Evidence map›Paper›PMID 37173716›Full record

ArticleBMC pulmonary medicine2023

Impact of a digital web-based asthma platform, a real-life study.

Emma M Genberg, Hilkka T Viitanen, Mika J Mäkelä, Hannu J Kautiainen, Paula M Kauppi

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Emma M GenbergAllergic Diseases, Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. emma.genberg@hus.fi.
Hilkka T ViitanenAllergic Diseases, Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mika J MäkeläAllergic Diseases, Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Hannu J KautiainenPrimary Health Care Unit, Kuopio University Hospital, Kuopio, Finland.
Paula M KauppiAllergic Diseases, Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
University of Helsinki · FIFolkhälsans Forskningscentrum · FIHelsinki University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDigital health technology (DHT) is a growing area in the treatment of chronic diseases. Study results on DHT's effect on asthma control have been mixed, but benefits have been seen for adherence, self-management, symptoms, and quality of life. The aim was to evaluate the impact of an interactive web-based asthma treatment platform on asthma exacerbations and health care visits.

methodsIn this real-life study, we retrospectively collected data on adult patients registered on a web-based interactive asthma treatment platform between December 2018 and May 2021. Patients who activated their accounts were active users, and patients who did not were inactive users and considered as controls. We compared the number of exacerbations, total number of exacerbation events defined as the sum of oral corticosteroid (OCS) and antimicrobial courses, emergency room visits, hospitalizations, and asthma-related health care visits before and one year after the registration on the platform. Statistical tests used included the t-test, Pearson's chi-square test and Poisson regression models.

resultsOf 147 patients registered on the platform, 106 activated their accounts and 41 did not. The active users had significantly fewer total number of exacerbation events (2.56 per person years, relative decline 0.78, 95% CI 0.6 to 1.0) and asthma-related health care visits (2.38 per person years, relative decline 0.84, 95% CI 0.74 to 0.96) than before registration to the platform, whereas the reductions in health care visits and the total number of exacerbation events were not significant in the inactive users.

conclusionsAn interactive web-based asthma platform can reduce asthma-related health care visits and exacerbations when used actively.

Indexed as

Anti-Asthmatic AgentsAsthmaAdrenal Cortex HormonesAdultHumansInternetQuality of LifeRetrospective StudiesAdrenal Cortex HormonesAnti-Asthmatic AgentsAsthma controlDigital health technologyExacerbationInteractiveSelf-managementWebsite

Identifiers

PMID37173716
PMCPMC10177708
OpenAlexW4376275157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.